In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

As of 11 a.m. ET, shares of Novo ... earnings growth of about 19%, we may be approaching the point where all the "bad" news will be "priced in," and there's nowhere left for Novo Nordisk stock ...

and human growth hormone. While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Bagsværd, Denmark-based Novo Nordisk is a global healthcare company ... The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.

JAKARTA, INDONESIA – media OutReach Newswire – 9 January 2025 – Novo Nordisk and AstraZeneca have been recognized as the top two best places to work in Indonesia for 2024, according to the prestigious ...